NextGen Scientific LLC has issued an updated announcement regarding its $10 million Regulation D, Rule 506(c) private placement offering, correcting and superseding a previously distributed press release that contained inaccurate information. The company is raising funds from accredited investors to acquire up to 3.1% ownership in Ionics Life Sciences Limited and its subsidiaries, including Genzada Pharmaceuticals USA and Hyatt Life Sciences.
Genzada Pharmaceuticals USA is an early-stage biotechnology company focused on oncology drug development with two clinical-stage candidates. GZ17-6.02, an oral compound, is being evaluated in a metastatic prostate cancer study at Virginia Commonwealth University after showing safety and efficacy in preclinical and clinical studies. GZ21T, a topical therapy for cancerous and precancerous skin conditions, is expected to receive regulatory approval in Q1 2026 to initiate a Phase 1b/2a clinical trial for actinic keratosis in Sweden and the Netherlands. Proceeds will primarily support clinical and preclinical programs for these candidates, along with drug manufacturing and development.
Hyatt Life Sciences is a revenue-generating nutraceutical and botanical sciences enterprise specializing in science-based dietary supplements, operating within the rapidly expanding global nutraceuticals market. Investors in the offering gain exposure to both clinical-stage drug development and a growing revenue-generating supplements business.
Dr. Cameron West, Chief Operating Officer, stated, “During our Phase I dose escalation study for GZ17-6.02, we observed promising biological effect against a broad array of cancer types and we are excited to further explore how this translates into meaningful clinical impact.” He added optimism regarding GZ21T's potential based on preclinical data and safety profile.
NextGen Scientific is building a diversified healthcare platform through strategic investment in Ionics Life Sciences, aiming to generate long-term value through clinical innovation and active revenue streams. For more information, visit https://investinnextgen.com/.
